Asset
RIDINILAZOLE
SUMMIT THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02784002 | phase2 | completed | 2014-12-01 | 2016-08-01 | Summit Therapeutics | A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) |
| NCT02092935 | phase2 | completed | 2014-04-01 | 2015-10-01 | Summit Therapeutics | A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) |
| NCT03595553 | phase3 | completed | 2019-01-28 | 2021-11-17 | Summit Therapeutics | Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection |
| NCT04802837 | phase3 | terminated | 2021-05-19 | 2021-09-17 | Summit Therapeutics | Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects |
FDA applications (0)
This company has no applications containing this asset.